1. Home
  2. WING vs RYTM Comparison

WING vs RYTM Comparison

Compare WING & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wingstop Inc.

WING

Wingstop Inc.

HOLD

Current Price

$130.70

Market Cap

4.9B

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$94.03

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WING
RYTM
Founded
1994
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.8B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
WING
RYTM
Price
$130.70
$94.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
27
14
Target Price
$295.92
$131.14
AVG Volume (30 Days)
1.4M
614.4K
Earning Date
04-29-2026
05-05-2026
Dividend Yield
0.70%
N/A
EPS Growth
67.84
28.34
EPS
1.08
N/A
Revenue
$696,853,000.00
N/A
Revenue This Year
$17.20
$55.34
Revenue Next Year
$15.86
$86.06
P/E Ratio
$123.95
N/A
Revenue Growth
11.35
N/A
52 Week Low
$133.80
$55.31
52 Week High
$388.14
$122.20

Technical Indicators

Market Signals
Indicator
WING
RYTM
Relative Strength Index (RSI) 24.84 61.47
Support Level N/A $82.09
Resistance Level $267.86 $100.70
Average True Range (ATR) 11.62 4.04
MACD -4.49 1.46
Stochastic Oscillator 1.08 74.59

Price Performance

Historical Comparison
WING
RYTM

About WING Wingstop Inc.

Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: